Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director · Chief Scientific Officer | June 07, 2022 | June 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,055,174 |
Ending reported balance
After 2022-06-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-06-07 · Exercise / conversion · Acquired 29,545 · Balance 4,061,824 F1: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Row 2 · 2022-06-07 · Exercise / conversion · Acquired 12,199 · Balance 4,074,023 F1: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Row 3 · 2022-06-08 · Sale · Disposed 18,849 · Balance 4,055,174 F3: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,545 |
Reported balance
After 2022-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-07 · Exercise / conversion · Disposed 29,545 · Balance 29,545 F2: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F4: On June 7, 2021 the Reporting person was granted RSUs, which vest in two equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,391 |
Reported balance
After 2022-06-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-06-07 · Exercise / conversion · Disposed 12,199 · Balance 24,391 F2: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F5: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022.
F2: Each RSU represents a contingent right to receive one share of the Company's Common Stock.
F3: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
F4: On June 7, 2021 the Reporting person was granted RSUs, which vest in two equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
F5: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2022 Filed Jun 9, 2022 20:42 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 18,849 | $2.06 | $38,828.94 |
DisclosureSEC source: 0001209191-22-035417 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,055,174 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:42 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 12,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035417 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,391 Underlying: Common Stock · 12,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:42 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 29,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035417 · doc4.xml · derivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,545 Underlying: Common Stock · 29,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F4 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in two equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F4 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in two equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:42 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 12,199 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-035417 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,074,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:42 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 29,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-035417 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 98,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016650 · doc4.xml · derivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,401 Underlying: Common Stock · 98,401 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 156,271 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001209191-22-016650 · doc4.xml · derivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,271 Underlying: Common Stock · 156,271 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 3, 2023 and vests in substantially equal installments at the end of each successive three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| February 22, 2022 Filed Feb 24, 2021 22:46 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-013922 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,626 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 36,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,590 Underlying: Common Stock · 36,590 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,875 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,875 Underlying: Common Stock · 62,875 shares Expires 2031-06-06 F4 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 59,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,090 Underlying: Common Stock · 59,090 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in two equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. F3 · derivative.expiration_date: The RSUs shall vest in two equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 101,537 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,537 Underlying: Common Stock · 101,537 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Any unvested options shall vest and become exercisable upon the Reporting Person's termination without cause or resignation due to good reason prior to June 7, 2022. Read SEC document |
| May 17, 2021 Filed May 19, 2021 12:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 20,000 | $9.38 | $187,600.00 |
DisclosureSEC source: 0001209191-21-033864 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032,279 F1 · kind: The sale was effected to cover the taxes incurred with the Reporting Person's previous option exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.21 to $9.63. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,673 | $9.17 | $88,701.41 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052,279 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,514 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,673 | $9.15 | $88,507.95 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040,438 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,028 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,676 | $8.72 | $84,374.72 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028,597 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,038,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,542 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,676 | $8.69 | $84,084.44 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,016,759 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.63 to $8.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,026,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,056 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,675 | $8.84 | $85,527.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004,921 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,570 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,676 | $8.76 | $84,761.76 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,993,082 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,084 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,665 | $11.08 | $107,088.20 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981,244 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,990,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,598 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,665 | $10.92 | $105,541.80 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,969,395 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,112 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,661 | $11.97 | $115,642.17 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,957,546 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.92 to $11.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,967,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:46 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,660 | $12.04 | $116,306.40 |
DisclosureSEC source: 0001209191-21-013922 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,945,693 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.08. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:46 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-013922 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,955,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,140 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,663 | $11.55 | $111,607.65 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,933,839 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.53 to $11.61. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,943,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,654 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 6,871 | $12.20 | $83,826.20 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921,988 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,928,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 22:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,515 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-006831 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,168 Underlying: Common Stock · 21,515 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 22:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 6,444 | $12.25 | $78,939.00 |
DisclosureSEC source: 0001209191-21-006831 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,907,345 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.